Castleman's disease in childhood: report of three cases and review of the literature
© Farruggia et al; licensee BioMed Central Ltd. 2011
Received: 6 August 2011
Accepted: 20 October 2011
Published: 20 October 2011
Castleman's disease (CD) is a rare, localized or generalized, lymphoproliferative disorder with a frequent mediastinal location, but possible in any lymph node or extra nodal site. It usually appears in young adults whilst it rarely occurs in childhood. There are only about 100 pediatric cases published, five of them in Italy. We report 3 cases of localized Castleman's disease, investigated in our Department in a 3 years period and reviewed the literature.
KeywordsCastleman's disease childhood differential diagnosis histological subgroups outcome
Castleman's disease (CD) is a rare and not well recognized disease characterized by a massive growth of lymphoid tissue of unknown etiology that was first described in 1954, and subsequently better defined by Castleman in 1956 [1, 2]. The disease usually presents in young adults and is probably slightly more frequent in women. CD is classified into two clinical subtypes: a localized and a multifocal subtype. CD may occur anywhere along the lymphatic system, although the most common location (70%) is the mediastinum. Extrathoracic sites have been reported in the neck, axilla, pelvis and retroperitoneum . Surgery is the optimal therapeutic approach only in the localized form, while for unresectable or disseminated disease, partial surgical resection, steroid, chemotherapy and radiotherapy have been employed with some measurable success.
We report three cases of localized hyaline-vascular CD in pediatric age observed in our Department in the last 3 years; a complete surgical resection was not feasible in one of them and so various therapeutic attempts were performed.
After prolonged and troublesome discussion with surgeons, an attempt of surgical excision was planned through a left trap door incision. This approach consisted of a left-anterior cervical access, median sternotomy and left-anterior thoracotomy that could provide adequate exposure of the neurovascular structures . The mass had a vascular aspect and encased the left internal jugular vein and the carotid artery down into the mediastinum. Repeated attempts to remove the lesion caused massive and life-threatening bleeding; therefore the procedure was prematurely interrupted and an abundant transfusion of red blood cells was performed.
Finally, after troubling discussion with the parents, the boy underwent a 45 Gy course of 3D conformal radiation therapy on the upper mediastinal mass, with standard fractionation of 1.8 Gy per day. The treatment was delivered through two antero-posterior, postero-anterior asymmetrically weighted beam pairs of different energies in order to encompass the mass into the 95% isodose. Particular care was taken to avoid undue radiation delivery to the nearby organs: right and left lungs received an average dose of 8 and 6.4 Gy respectively, while the spinal cord maintained a maximum dose less than 45 Gy. A CT scan performed at two months from the end of radiotherapy showed a reduction of the mass by about 60% and a significant improvement of tracheal dislocation: both were more evident in a second CT scan performed 3 months later. The FDG-PET scan that initially revealed a mildly significant uptake of the radiopharmaceutical of the residual disease at three months from the end of radiotherapy, became totally negative after a further 3 months, confirming the effectiveness of our therapy choice. A further reduction of the residual mass sizes and negative total body scan was obtained six months later with neck-chest CT scan and FDG-PET scan respectively. Now the boy is well, on a watchful follow-up, without any side effect of radiotherapy, 12 months after discontinuation of treatment.
Histologically all of our cases, diagnosed as hyaline-vascular type of Castleman's disease, showed a mass of lymphoid tissue with scattered abnormal lymphoid follicles, which ranged in size from small to large. The germinal centers were depleted and composed predominantly of follicular dendritic cells and endothelial cells of hyalinized capillaries. Their appearance corresponds to that of "hyaline vascular nodules". Another peculiar finding was the presence of more than one small germinal center within a single follicle. There was a concentric layering of lymphocytes at the periphery of the follicles with an onion-skin appearance.
The interfollicular areas showed vascular proliferation with numerous hyperplastic vessels of the postcapillary venule type with hyaline material between vessels and absence of sinuses. A small number of lymphocytes, plasmacells, eosinophils and immunoblasts were present.
Immunohistochemically, positive CD21 and CD35 were seen in the large cells with vesicular nuclei (follicular dendritic cells) in the center of follicles, strong positive FVIII-related antigen was seen in the endothelium of the interfollicular vessels, but only weak and focal reaction was found in the hyaline vessels located in the center of the follicles.
The immunoglobulin production by plasmacells was polytypic and in the interfollicular areas large numbers of suppressor T cells were found.
In summary the diagnostic features were small hyaline germinal centers within an expanded mantle zone, as well as a highly vascularized interfollicular network.
CD is a disease of unknown etiology, first described by Castleman in 1956  and currently classified in two subgroups: localized (only one group of lymph nodes involved) and disseminated (two or more lymph nodal groups involved). Localized disease seems to be much more frequent, above all in the case of thoracic presentation [4, 5]. There are three major histological subtypes: hyaline-vascular CD (HV-CD), plasma cell CD (PC-CD) and a plasmablastic variant associated with HHV8 and HIV. The first is much more frequent (91-96%) [5, 6]. The majority (57-91%) of localized disease is hyaline-vascular [7, 8]. Most cases of disseminated CD are PC-CD variants or plasmablastic variants in HIV+ patients [8, 9]. The prognosis of the disseminated PC-CD is worse whereas disseminated variants with HV-CD histology or with a mixed appearance between HV-CD and PC-CD seem to have a better course [3, 8–11].
Prevalence is estimated to be less than 1/100,000 . There are some series where female sex is predominant [4, 13, 14], but in many others there is no sex predilection [6–8]. The peak of incidence is in the third and fourth decade of life for localized CD and in the fourth and fifth decade of life for disseminated CD [7, 8, 13].
It is postulated that the disease represents a reaction to chronic viral antigenic stimulation with the bulk of evidence pointing toward an interleukin-6 role, above all in the form of the disease associated with systemic manifestations [15–17]. The large majority of cases don't show lymphocyte monoclonality . In many cases the HHV-8 has been postulated as the virus capable of causing the disease, above all in multicentric cases [19, 20].
The majority of HV-CD at presentation is asymptomatic but, in some cases, fever, night sweat or weight loss can be present; in contrast, if the localized disease has a plasma cell histology, constitutional symptoms are very frequent, as in the disseminated form [7, 8]. The site of presentation can be abdominal, mediastinal or peripheral and the frequency of involvement reported in the literature is variable [6, 8, 23]. The CD located in the thorax can be found in mediastinum (anterior above all, but middle and posterior too) and, rarely, in the chest wall, pleura, pericardium, intercostal space, and lung [5, 24, 25]. Usually the mediastinal masses are wide and most of the thoracic cases are asymptomatic at presentation; sometimes there are symptoms connected to local pressure from the mass (cough, chest pain, dyspnoea etc.). Invasion and adherence to vessels and bronchi are common patterns and often the mass proves difficult to complete resection, as in our case . When the location is abdominal the presentation sometimes includes abdominal pain .
The plasma cells and/or the multicentric CD present with a variety of constitutional symptoms: peripheral lymphadenopathy, hepatosplenomegaly, weight loss, anemia, asthenia, night sweats, fever, skin rash, lung disorder and kidney dysfunction [8, 25, 27].
Less common presentations are polyneuropathy, pleural effusion, ascites etc. [23, 28]. Typically there are also laboratory abnormalities: elevated serum concentration of gamma globulin and acute phase proteins, thrombocytosis, elevated ESR, low serum albumin level, proteinuria, and, sometimes, elevated IL-6, especially in the plasma cell systemic disease .
Enhancement on CT images after intravenous administration is universally reported but it seems that the enhancement is to a lesser degree in the plasma cell variant. At MRI the T1 weighted images are isointense or slightly hyperintense relative to the skeletal muscle; the hyperintensity is much more evident on T2 weighted images .
About the therapy issue, it is difficult to draw definitive conclusions for both local and disseminated CD, but some broad indications can be found.
Since the recurrence of localized CD is very unusual when the resection is complete, surgery is the preferred treatment in these cases [6–8, 29–31]. When a complete resection is impossible, in the case of unicentric hyaline-vascular disease, partial resection and/or, radiation therapy with doses ranging from 27 to 45 Gy are a possibility [7, 32, 33]. It has been reported that with these treatments some patients can remain asymptomatic "long term" and that, even in the case of mediastinal disease, simple partial resection without any extra treatment has not been followed by recurrence . Surprisingly there are very few cases where steroid therapy has been attempted, but this could be explained by the fact that complete resection is easily performed in all non-mediastinal sites and that radiotherapy is traditionally preferred in the case of mediastinal lymphoma . It is important to note, however, that there are some case reports where the disease, without any treatment, remains asymptomatic or shows a gradual spontaneous improvement and even complete remission [7, 8]. The location of the lymphadenopathy has no influence on the outcome .
Even though cases of spontaneous remission have been described , the course of disseminated CD, especially in the plasma cell form, is often reported poor due to complications like infections, severe autoimmune anemia, sarcoidosis, amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal antibody, skin changes), and evolution into malignant neoplasm, principally lymphoma, follicular dendritic cell sarcoma or, especially in HIV positive patients, Kaposi sarcoma [8, 15, 18, 34, 35].
In some more recent series, however, the prognosis seems to have been better . The treatment of the disseminated form is not well documented but chemotherapy has been successful in many cases [3, 7, 8]. Regimens against Hodgkin Lymphoma are the most commonly used, even in childhood . The role of radiotherapy is more uncertain than in the localized form, since there are cases where it proved to be useful and others where there was no response [11, 37]. In some cases steroids alone can be sufficient for remission even though the treatment must often be prolonged; it is possible that the response to steroids can have a prognostic value [8, 10, 38]. Finally there are some sporadic cases where experimental therapies like autologous hematopoietic stem-cell transplantation, rituximab, valganciclovir, tocilizumab (an anti-IL-6 receptor antibody), interferon-alpha, anakinra - an IL-1RA agonist - and, more recently, siltuximab, a new anti-IL-6 chimeric monoclonal antibody, have been used with some success [21, 39–44]. Since the treatment of our first two patients was an easy uncomplicated complete surgical resection, we should add some comments about therapy strategies in our third patient, that could not be surgically resected completely. When this option is impossible the most important aspects to consider are the volume and location of the mass: probably in sites not "at risk" careful observation is the best option and radiotherapy can be taken into account in other cases.
Our experience also emphasizes the potential hazards of surgical resection depending on the location and vascular characteristics of the Castleman's disease: the second surgical attempt was prematurely stopped due to serious life-threatening bleeding. Probably, a preoperative embolization could be a safety precaution before of a surgical approach on a HV-CD variant . Between the two surgical procedures we first attempted a trial with steroid (prednisone 25 mg × 3/day) for 2 months, that totally failed; subsequently we performed a trial with administration of vinblastine weekly for 8 doses, without any response. After the ineffective surgical procedure we were extremely troubled in the treatment decision making and, finally, opted for local radiotherapy for the following considerations: a) some authors reported the effectiveness of lymphoma-like multiagent chemotherapy, such as CVAD or CHOP schedule, but only in multicentric CD, that represents a more aggressive clinical entity ; b) our patient suffered from a localized CD, and radiotherapy, as reported by some authors, can also achieve a good clinical response ; c) our patient was a big pubertal male (weight 68 Kg and height 171 cm), in which consequences of breast exposure to radiation or growth abnormalities are fairly improbable. On the contrary, the risk of cardiac dysfunction, growth abnormalities and secondary malignancies may limit the application of radiotherapy in other pediatric patients (pre-pubertal and females).
Thus we planned local radiotherapy, choosing a total dose of 45 Gy, that had good results, as previously reported in the literature . CT scan evaluation showed a marked reduction of the mass and a significant reduction of tracheal dislocation, and there was an absolute disappearance of the radiopharmaceutical uptake in the last FDG-PET scans, performed 6 and 12 months after the end of radiation treatment.
1PF, AT and PD are physicians of Pediatric Hematology and Oncology Unit, at "G. Di Cristina" Children's Hospital, Palermo. They are AIEOP (Italian Association of Pediatric Hematology and Oncology) members. PF has a peculiar experience in the field of pediatric lymphoma and non oncologic hematology, AT has particularly developed his activity in the field of primary immunodeficiency and histiocytic disorders, while PD is especially involved in the management of children and adolescents with solid tumors.
2NS, from Unit of Pathology, "Civico e Benfratelli" Hospital, A.R.N.A.S., Palermo, Italy.
3GC, from Pediatric Surgery Department, University of Padua, is chairman of GICOP (Italian Group of Pediatric Oncologic Surgery), SIOP member and co-chairman in various international pediatric oncology trials.
4PG, from Unit of Oncological Radiotherapy, "Civico e Benfratelli" Hospital, A.R.N.A.S., Palermo, Italy.
5ESGD, from Unit of Pathology, San Bortolo Hospital, Vicenza, Italy. ESGD is one of the AIEOP referring pathologist in the field of Hodgkin and non-Hodgkin Lymphoma.
Written informed consent was obtained from the patients' parents for publication of these case reports and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
List of abbreviations
- 99 mTc-MDP:
phospho-di-glicerato-positron emission tomography
cluster differentiation 21
cluster differentiation 35
human herpes virus 8
human immunodeficiency virus
magnetic resonance imaging
polyneuropathy, organomegaly, endocrinopathy, monoclonal antibody, skin changes syndrome
The authors are grateful to Prof. Frank Adamo for language support, and to the parents' Association "A.S.L.T.I.-Liberi di crescere" Onlus for the financial support.
- Castleman B, Towne VW: Case records of the Massachusetts General Hospital: case 32-1984. N Engl J Med. 1954, 311: 388-98.Google Scholar
- Castleman B, Iverson L, Menendez VP: Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer. 1956, 9: 822-30. 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF: The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999, 85: 706-17. 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Kraus DH, Huo J, Burt M: Surgical access to tumors of the cervicothoracic junction. Head Neck. 1995, 17 (2): 131-6. 10.1002/hed.2880170210.View ArticlePubMedGoogle Scholar
- McAdams HP, Rosado-de-Christenson M, Fishback NF, Templeton PA: Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation. Radiology. 1998, 209: 221-8.View ArticlePubMedGoogle Scholar
- Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972, 29: 670-83. 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
- Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD: Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001, 92: 670-6. 10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Herrada J, Cabanillas F, Rice L, Manning J, Pugh W: The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998, 128 (8): 657-62.View ArticlePubMedGoogle Scholar
- Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H: Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol. 1985, 16: 162-72. 10.1016/S0046-8177(85)80065-4.View ArticlePubMedGoogle Scholar
- Frizzera G, Peterson BA, Bayrd ED, Goldman A: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985, 3 (9): 1202-16.PubMedGoogle Scholar
- Peterson BA, Frizzera G: Multicentric Castleman's disease. Semin Oncol. 1993, 20 (6): 636-47.PubMedGoogle Scholar
- Dégot T, Métivier AC, Casnedi S, Chenard MP, Kessler R: Thoracic manifestations of Castleman's disease. Rev Pneumol Clin. 2009, 65 (2): 101-7. 10.1016/j.pneumo.2008.12.004.View ArticlePubMedGoogle Scholar
- Kasantikul V, Panyavoravut V, Benjavongkulchai S, Panichabhongse V: Castleman's disease: a clinicopathologic study of 12 cases. J Med Assoc Thai. 1997, 80 (3): 195-201.PubMedGoogle Scholar
- Smir BN, Greiner TC, Weisenburger DD: Multicentric angiofollicular lymph node hyperplasia in children: a clinicopathologic study of eight patients. Mod Pathol. 1996, 9 (12): 1135-42.PubMedGoogle Scholar
- Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989, 74 (4): 1360-7.PubMedGoogle Scholar
- Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW: Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990, 86 (2): 592-9. 10.1172/JCI114749.PubMed CentralView ArticlePubMedGoogle Scholar
- Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D: Interleukin-6 gene expression in Castleman's disease. Blood. 1991, 78 (11): 2923-30.PubMedGoogle Scholar
- Soulier J, Grollet L, Oksenhendler E, Micléa JM, Cacoub P, Baruchel A, Brice P, Clauvel JP, d'Agay MF, Raphael M, Sigaux F: Molecular analysis of clonality in Castleman's disease. Blood. 1995, 86 (3): 1131-8.PubMedGoogle Scholar
- Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C: HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000, 95 (4): 1406-12.PubMedGoogle Scholar
- Amin HM, Medeiros LJ, Manning JT, Jones D: Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman's disease. Am J Surg Pathol. 2003, 27 (1): 91-100. 10.1097/00000478-200301000-00010.View ArticlePubMedGoogle Scholar
- Oksenhendler E: HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009, 4 (1): 16-21. 10.1097/COH.0b013e328319bca9.View ArticlePubMedGoogle Scholar
- Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M: The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009, 20 (4): 775-9. 10.1093/annonc/mdn697.View ArticlePubMedGoogle Scholar
- Kim TJ, Han JK, Kim YH, Kim TK, Choi BI: Castleman disease of the abdomen: imaging spectrum and clinicopathologic correlations. J Comput Assist Tomogr. 2001, 25 (2): 207-14. 10.1097/00004728-200103000-00008.View ArticlePubMedGoogle Scholar
- Ueda H, Kouso H, Tsukamoto S: Castleman's disease of the chest wall. J Thorac Oncol. 2009, 4 (3): 426-8. 10.1097/JTO.0b013e3181989edc.View ArticlePubMedGoogle Scholar
- Ko SF, Wan YL, Ng SH, Lin JW, Hsieh MJ, Fang FM, Lee TY, Chen WJ: Imaging features of atypical thoracic Castleman disease. Clin Imaging. 2004, 28 (4): 280-5. 10.1016/S0899-7071(03)00202-X.View ArticlePubMedGoogle Scholar
- Kim SH, Min BW, Kim WB, Park SS, Um JW, Lee JB, Mok YJ, Choi SY, Moon HY, Koo BH, Lee JH, Kim IS: Mesenteric Castleman's disease. Yonsei Med J. 2005, 46 (2): 289-91. 10.3349/ymj.2005.46.2.289.PubMed CentralView ArticlePubMedGoogle Scholar
- Lui SL, Chan KW, Li FK, Cheng IK, Chan TM: Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron. 1998, 78 (3): 323-7. 10.1159/000044943.View ArticlePubMedGoogle Scholar
- Blankenship ME, Rowlett J, Timby JW, Roth RS, Jones RE: Giant lymph node hyperplasia (Castleman's disease) presenting with chylous pleural effusion. Chest. 1997, 112 (4): 1132-3. 10.1378/chest.112.4.1132.View ArticlePubMedGoogle Scholar
- Yaris N, Cakir M, Kalyoncu M, Yildiz K, Okten A: Castleman disease: a case with atypical presentation. Pediatr Hematol Oncol. 2004, 21 (3): 203-8. 10.1080/08880010490276908.View ArticlePubMedGoogle Scholar
- Ohara K, Narita K, Ishikawa H, Kobayashi Y, Atsuta S, Matsumura Y, Murayama H: Local recurrence of Castleman disease. Kyobu Geka. 2009, 62 (2): 136-9.PubMedGoogle Scholar
- Robert JH, Sgourdos G, Kritikos N, Didier D, Terraz S: Preoperative embolization of hypervascular Castleman's disease of the mediastinum. Cardiovasc Intervent Radiol. 2008, 31 (1): 186-8. 10.1007/s00270-006-0156-y.View ArticlePubMedGoogle Scholar
- Palma DA, Dar AR, Millington SJ, Smits CL, Rizkalla K, Inculet R: Castleman's disease in children: report of 2 cases and clinicopathologic review. J Pediatr Hematol Oncol. 2004, 26 (4): 264-6. 10.1097/00043426-200404000-00011.View ArticlePubMedGoogle Scholar
- Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA: Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findings. Cancer. 1991, 68 (6): 1365-72. 10.1002/1097-0142(19910915)68:6<1365::AID-CNCR2820680630>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Boulanger E, Brière J, Gaulard P, Droz D, Oksenhendler E: HHV8-related non-Hodgkin's lymphoma of the spermatic cord in a patient with HIV-associated multicentric Castleman disease. Am J Hematol. 2003, 72 (1): 70-1. 10.1002/ajh.10246.View ArticlePubMedGoogle Scholar
- Marzano AV, Vezzoli P, Mariotti F, Boneschi V, Caputo R, Berti E: Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br J Dermatol. 2005, 153 (1): 214-5. 10.1111/j.1365-2133.2005.06695.x.View ArticlePubMedGoogle Scholar
- Baserga M, Rosin M, Schoen M, Young G: Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol. 2005, 27 (12): 666-9. 10.1097/01.mph.0000193468.06938.93.View ArticlePubMedGoogle Scholar
- Marti S, Pahissa A, Guardia J, Moragas A, Bacardi R: Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy. Cancer. 1983, 51 (5): 808-10. 10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
- Summerfield GP, Taylor W, Bellingham AJ, Goldsmith HJ: Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol. 1983, 36 (9): 1005-11. 10.1136/jcp.36.9.1005.PubMed CentralView ArticlePubMedGoogle Scholar
- Ganti AK, Pipinos I, Culcea E, Armitage JO, Tarantolo S: Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005, 79 (3): 206-10. 10.1002/ajh.20280.View ArticlePubMedGoogle Scholar
- Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P, Gazzard B, Nelson M, Stebbing J: Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009, 113 (19): 4521-4. 10.1182/blood-2008-12-197053.View ArticlePubMedGoogle Scholar
- Kanda J, Kawabata H, Yamaji Y, Ichinohe T, Ishikawa T, Tamura T, Furukawa Y, Kimura T, Kita T, Uchiyama T: Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol. 2007, 85 (3): 207-11. 10.1532/IJH97.06186.View ArticlePubMedGoogle Scholar
- Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994, 330 (9): 602-5. 10.1056/NEJM199403033300904.View ArticlePubMedGoogle Scholar
- Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I: IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. J Pediatr Hematol Oncol. 2008, 30 (12): 920-4. 10.1097/MPH.0b013e31818ab31f.View ArticlePubMedGoogle Scholar
- van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R: Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. J Clin Oncol. 2010, 28 (23): 3701-3708. 10.1200/JCO.2009.27.2377.View ArticlePubMedGoogle Scholar
- de Vries IA, van Acht MM, Demeyere TB, Lybeert ML, de Zoete JP, Nieuwenhuijzen GA: Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol. 2010, 5: 7-10.1186/1748-717X-5-7.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.